Yahoo Finance

Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

“We are honored to be the first facility to implant EluPro,” said Dr. Catanzaro. “With its combination of proven antibiotics and biomatrix with demonstrated regenerative benefits, EluPro offers a more ...
Yahoo Finance

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been ...
Nasdaq

Elutia Inc. Reports 18% Increase in BioEnvelope Sales Driven by EluPro Commercialization

Elutia Inc. reported an 18% increase in BioEnvelope sales and a significant 65% rise in same-center sales attributed to the pilot launch of EluPro, its new antibiotic-eluting biomatrix product, which ...
Nasdaq

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

(1) Represents interest expense recorded on all outstanding long-term debt as well as the revenue interest obligation. (2) Represents FiberCel litigation costs consisting primarily of legal fees and ...
Yahoo Finance

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and ...
Stockhouse

Elutia Announces First Patient Implant of EluPro(TM), the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement ...